HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: Genotypic-phenotypic correlations [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 5, 2004, Pages 1104-1107

  Torti, Carlo ^a   Quiros Roldan, Eugenia ^a   Monno, Laura ^b   Patroni, Andrea ^c   Saracino, Annalisa ^d   Angarano, Gioacchino ^d   Tinelli, Carmine ^c   Lo Caputo, Sergio ^e   Pierotti, Piera ^e   Mazzotta, Francesco ^e   Carosi, Giainpiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

^e SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTIRETROVIRUS AGENT; DIDANOSINE; DIDEOXYNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE;

AMINO ACID SEQUENCE; COHORT ANALYSIS; CORRELATION ANALYSIS; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LETTER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; COHORT STUDIES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; PHENOTYPE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 3342988011     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200408150-00016     Document Type: Letter

References (10)

1. Torti C, Quiros-Roldan E, Keulen W, et al. Comparison between rules-based HIV-1 genotype interpretations and real-phenotype or virtual-phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. J Infect Dis. 2003;188:194-201.
2. De Luca A, Cingolani A, Di Giambenedetto S, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic HIV-1 drug resistance. J Infect Dis. 2003;187:1934-1943.
3. Shafer RW. Genotypic testing for HIV type 1 drug resistance. Clin Microbiol Rev. 2002;15:247-277.
4. Mazzotta F, Lo Caputo S, Torti C, et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr. 2003;32:268-280.
5. Saracino A, Angarano G, PhenGen Study Group. Change of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open label, randomized, multicentre study (PhenGen). HIV Med. 2003;4:176.
6. Johnson VA, Brun-Vezinet F, Clotet B, et al. Drug resistance mutations in HIV-1. Top HIV Med. 2003;11:215-221.
7. Katzenstein D, Bosch RT, Wang N, et al. Baseline phenotypic susceptibility and virologie failure over 144 weeks among nucleoside RT inhibitor-experienced subjects in ACTG 364. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 2002.
8. Swanstrom R, Cheng H, Hellmann N, et al. Alternative phenotypic sensitivity scores and outcome measures increase detection of the impact of drug resistance on response to salvage therapy-results from ACTG 359. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 2002.
9. Shulman NS, Hughes MD, Winters MA, et al. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine experienced patients. J Acquir Immune Defic Syndr. 2002;31:121-127.
10. Harrigan PR, Montaner JS, Wegner SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS. 2001;15:1671-1677.